SPEXIS AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0522 CHF | -11.22% |
|
-11.53% | +27.32% |
| 05-01 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
| 04-17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 4.33M | - | - | - | - | - | |
| 86.16B | ||||||
| 40.17B | ||||||
| 31.47B | ||||||
| 25.24B | ||||||
| 15.82B |
- Stock Market
- Equities
- POLN Stock
- Charts Spexis AG
- Sector Chart
